RAF1 and central nervous system cancer: Classification: Pan-RAF inhibitor. Side effects: rash and increased bilirubin in once-a-week treatment for ST or melanoma detected in Phase I. Phase I is recruiting for gliomas and other tumors (NCT03429803)